{
    "organizations": [],
    "uuid": "9a1aaadbb6a4723a410d8fb2270296824e8b4914",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-reports-q4/brief-syndax-pharmaceuticals-reports-q4-loss-per-share-0-80-idUSASB0C8UP",
    "ord_in_thread": 0,
    "title": "BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE\n* Q4 LOSS PER SHARE $0.80 * SYNDAX PHARMACEUTICALS - FOR Q1 AND FY 2018, TOTAL OPERATING EXPENSES ARE EXPECTED TO BE $22 TO $26 MILLION AND $86 TO $96 MILLION, RESPECTIVELY\n* Q4 EARNINGS PER SHARE VIEW $-0.78 â€” THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T05:36:00.000+02:00",
    "crawled": "2018-03-06T22:27:29.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "syndax",
        "pharmaceutical",
        "inc",
        "syndax",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "provides",
        "clinical",
        "business",
        "update",
        "q4",
        "loss",
        "per",
        "share",
        "syndax",
        "pharmaceutical",
        "q1",
        "fy",
        "total",
        "operating",
        "expense",
        "expected",
        "million",
        "million",
        "respectively",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}